All other cannabinoids, produced in any other setting, remain a Schedule I compound under federal law and are therefore prohibited. (The one exception is pharmaceutical-grade CBD products that have been approved by FDA, which presently consists of one drug: GW Pharmaceutical's Epidiolex.) There is one additional gray area of research study progressing.
That setup exists because of cannabis's Schedule I status. Nevertheless, if hemp-derived CBD is no longer noted on the federal schedules, it will raise concerns amongst medical and scientific researchers studying CBD items and their results, regarding whether they are required to get their items from Mississippi. This will likely need additional assistance from FDA (the Fda who supervises drug trials), DEA (the Drug Enforcement Administration who mandates that research-grade marijuana be sourced from Mississippi), and NIDA (National Institute on Drug Abuse who administers the contract to cultivate research-grade marijuana) to assist ensure researchers do not unintentionally run out of compliance.
Over the past 22 years, 33 states have actually legalized marijuana for medical functions, and over the past six years, 10 states have legalized cannabis for adult use. Every one of those programs is prohibited under federal law, without any exceptions, and the Farm Expense does nothing to alter that. That said, lots of in the advocacy community hope that the reforms to hemp policy under the Farm Expense work as an initial step toward more comprehensive marijuana reform.
This legal reality is an essential distinction for consumer protection. There are numerous misconceptions about the legality of CBD items and their availability. Under the 2018 Farm Expense, there will be more broadly available, legal, CBD products; nevertheless, this does not imply that all CBD items are legal moving forward.